Royalty Pharma plc Class A Ordinary Shares vs Vanguard High Dividend Yield ETF — how do they compare? Royalty Pharma plc Class A Ordinary Shares trades at $57.04 (market cap $25.27B), while Vanguard High Dividend Yield ETF trades at $158.79 (market cap $100.80B). The key difference: Vanguard High Dividend Yield ETF is far larger — about 4× Royalty Pharma plc Class A Ordinary Shares's market cap, and Royalty Pharma plc Class A Ordinary Shares pays a 1.66% dividend while Vanguard High Dividend Yield ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Royalty Pharma plc Class A Ordinary Shares for 0 Days and Vanguard High Dividend Yield ETF for 138 Days on average.
| RPRX | VYM | |
|---|---|---|
Market Cap | $25.27B | $100.80B |
Volume | 3,671,183 | 908,176 |
Sector | Health | — |
52-Week High | $63.96 | $167.03 |
52-Week Low | $35.44 | $137.47 |
Typical Hold Time | 0 Days | 138 Days |
Enterprise Value | $32.50B | — |
Dividend Yield | 1.66% | — |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
VYM trades at $158.56, up 0.7% with a bearish technical signal from moving averages. The ETF faces mixed sentiment as articles highlight its consistent dividend yield of 2.42% but note underperformance versus peers like SCHD and IDV. Support sits at $156, with resistance at $159-160. Recent news questions its stock selection methodology after holding Intel and Walgreens through dividend cuts.
Outlook remains cautious due to technical bearishness and competitive pressure from higher-yielding alternatives. Risks include sector concentration in dividend-cut-prone stocks and inflation persistence. Opportunities lie in its low expense ratio and broad diversification across nearly 600 holdings for income-focused investors.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Royalty Pharma acquires interests in royalties from biopharmaceutical products. Its model gives it exposure to medicines developed and sold by other life sciences companies.
Read more on RPRX →The advisor employs an indexing investment approach designed to track the performance of the index, which consists of common stocks of companies that pay dividends that generally are higher than average. The advisor attempts to replicate the target index by investing all, or substantially all, of the fund's assets in the stocks that make up the index, holding each stock in approximately the same proportion as its weighting in the index.
Read more on VYM →